MedTrace Logo

To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers

NCT05463497 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-07-19

No results posted yet for this study

Summary

A randomized, open-label, multiple-dose, 2x3 crossover clinical trial to investigate the pharmacokinetic drug interaction of JW0201 and C2103 or C2104 after oral administration in healthy adults

Conditions

  • Healthy

Interventions

DRUG

Treatment A

JW0201: single administration, Tablet, Oral, BID for 5 days

DRUG

Treatment B

C2103: single administration, Tablet, Oral, BID for 5 days

DRUG

Treatment C

JW0201 and C2103 : combination administration, Tablet, Oral, BID for 5 days

DRUG

Treatment D

C2104 : single administration, Tablet, Oral, QD for 5 days

DRUG

Treatment E

JW0201 and C2104 : combination administration, JW0201 twice a day and C2104 once a day for 5days

Sponsors & Collaborators

Principal Investigators

  • Min-Gul Kim, PI · Jeonbuk National University Hospita

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-17
Primary Completion
2022-03-16
Completion
2022-03-23

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05463497 on ClinicalTrials.gov